

February 20, 2026

Company name: Astena Holdings Co., Ltd.
Name of representative: Satoshi Setoguchi, President & CEO
(Securities code: 8095; TSE Prime Market)
Inquiries: Takayuki Okabe, General Manager,
Corporate Planning Department
(TEL: +81-3-3279-0481)

Announcement Regarding Receipt of Dividend from Consolidated Subsidiary

Astena Holdings Co., Ltd. (the “Company”) hereby announces that the Company will receive a dividend from its consolidated subsidiary. As this matter falls under the requirements for submission of an Extraordinary Report pursuant to the provisions of Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 12 of the Cabinet Office Order on Disclosure of Corporate Affairs, the Company provides the following information.

1. Overview of dividend

- | | |
|----------------------------------|--|
| (1) Dividend amount: | 458 million yen |
| (2) Dividend payer: | One consolidated subsidiary (SPERA PHARMA, Inc.) |
| (3) Date of dividend resolution: | February 20, 2026 (Date of resolution at the general meeting of shareholders of the consolidated subsidiary) |
| (4) Date of dividend receipt: | February 24, 2026 |

2. Impact on financial results

The dividend to be received will be recorded as operating revenue in the non-consolidated financial statements of the Company for FY11/2026. As the dividend is received from a consolidated subsidiary, there will be no impact on the Company’s consolidated financial results for FY11/2026.

[Inquiries]
Astena Holdings Co., Ltd.
Corporate Planning Department
TEL: +81-3-3279-0564